Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes
Management of multiple sclerosis patients in central European countries: current needs and potential solutions
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
Treatment sequencing in multiple sclerosis: The benefits of disease-modifying therapies - touchNEUROLOGY
Eva Kubala Havrdová - Proč nepodléhat strachu | RS kompas
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis | NEJM
Solen: On-line kurz pro praktické neurology 2/2022 - Léčba pacienta s RS v průběhu dekád života
Nové informace ke Covid 19 a RS - prof. Havrdová | RS kompas
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic - Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal, , The
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study – ScienceOpen
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges - Angelo Ghezzi, Maria Pia Amato, Gilles Edan, Hans-Peter Hartung, Eva Kubala Havrdová, Ludwig Kappos, Xavier Montalban, Carlo Pozzilli,
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
MUDr. Havrdová: Nová kritéria diagnostiky RS | RS kompas
Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis
PDF) Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ | Eva Havrdova - Academia.edu
Clinical Advances in MS: Changing the Future for Patients
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate_ Experiences of an international
Prezentace aplikace PowerPoint
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study | PLOS ONE
Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield proces
Eva K. Havrdová: Nové trendy v léčbě RS | RS kompas
PDF) Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Multiple sclerosis today: Disease monitoring, biomarkers and family planning - touchNEUROLOGY
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
Multiple Sclerosis dataBase Independent predictors of time to relapse after CIS in high-risk patients Tim Spelman 1*, Claire Meyniel 1,2*, Maria Trojano. - ppt download
Eva HAVRDOVA | Charles University in Prague, Prague | CUNI | Department of Neurology (2. LF) | Research profile
